Cargando…

N-acetyl Cysteine Use in the Treatment of Shock Liver

Acute liver failure is a rare, life-threatening illness accounting for about 7% of all liver-related deaths. Patients with acute liver failure are managed with supportive care initially, and if supportive care fails, liver transplantation is the definitive option for eligible candidates in liver fai...

Descripción completa

Detalles Bibliográficos
Autores principales: Parvataneni, Swetha, Vemuri-Reddy, Sireesha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108670/
https://www.ncbi.nlm.nih.gov/pubmed/32257694
http://dx.doi.org/10.7759/cureus.7149
_version_ 1783512820599488512
author Parvataneni, Swetha
Vemuri-Reddy, Sireesha
author_facet Parvataneni, Swetha
Vemuri-Reddy, Sireesha
author_sort Parvataneni, Swetha
collection PubMed
description Acute liver failure is a rare, life-threatening illness accounting for about 7% of all liver-related deaths. Patients with acute liver failure are managed with supportive care initially, and if supportive care fails, liver transplantation is the definitive option for eligible candidates in liver failure. N-acetyl cysteine (NAC) has a well-established role in acetaminophen-induced liver failure and has been reported to reduce mortality in these patients. It has also been reported to provide benefit in non-acetaminophen-induced liver failure secondary to infection, drugs, and toxins. Here we report an interesting case of NAC use in an elderly patient with shock liver secondary to severe sepsis in whom liver transplantation was not an option.
format Online
Article
Text
id pubmed-7108670
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-71086702020-04-02 N-acetyl Cysteine Use in the Treatment of Shock Liver Parvataneni, Swetha Vemuri-Reddy, Sireesha Cureus Internal Medicine Acute liver failure is a rare, life-threatening illness accounting for about 7% of all liver-related deaths. Patients with acute liver failure are managed with supportive care initially, and if supportive care fails, liver transplantation is the definitive option for eligible candidates in liver failure. N-acetyl cysteine (NAC) has a well-established role in acetaminophen-induced liver failure and has been reported to reduce mortality in these patients. It has also been reported to provide benefit in non-acetaminophen-induced liver failure secondary to infection, drugs, and toxins. Here we report an interesting case of NAC use in an elderly patient with shock liver secondary to severe sepsis in whom liver transplantation was not an option. Cureus 2020-02-29 /pmc/articles/PMC7108670/ /pubmed/32257694 http://dx.doi.org/10.7759/cureus.7149 Text en Copyright © 2020, Parvataneni et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Parvataneni, Swetha
Vemuri-Reddy, Sireesha
N-acetyl Cysteine Use in the Treatment of Shock Liver
title N-acetyl Cysteine Use in the Treatment of Shock Liver
title_full N-acetyl Cysteine Use in the Treatment of Shock Liver
title_fullStr N-acetyl Cysteine Use in the Treatment of Shock Liver
title_full_unstemmed N-acetyl Cysteine Use in the Treatment of Shock Liver
title_short N-acetyl Cysteine Use in the Treatment of Shock Liver
title_sort n-acetyl cysteine use in the treatment of shock liver
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108670/
https://www.ncbi.nlm.nih.gov/pubmed/32257694
http://dx.doi.org/10.7759/cureus.7149
work_keys_str_mv AT parvataneniswetha nacetylcysteineuseinthetreatmentofshockliver
AT vemurireddysireesha nacetylcysteineuseinthetreatmentofshockliver